No Picture
News

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral dis… […]

No Picture
News

Gilead loses two more patent challenges on HIV pill, setting up courtroom fight in Delaware

Gilead sustained two more losses in their efforts to rid themselves of an activist-backed patent lawsuit from the US government over a best-selling HIV pill.
Urged on by activists seeking to divert a portion of Gilead’s revenue to clinics and preventio… […]

No Picture
News

Bankrupt antibiotics maker Aradigm turns to old partner/investor for final $3M fire sale

Grifols once paid Aradigm $26 million for a stake in its inhaled antibiotics. But with Aradigm now in bankruptcy, the Spanish drugmaker is dishing out a final $3.2 million to buy it all.
The fire sale — which comes one year after Aradigm filed for Chap… […]

No Picture
News

eFFECTOR co-founder Siegfried Reich jumps to Turning Point; Antonio Gualberto starts post-Kura career at Eisai subsidiary H3

→ Seasoned drug hunter Siegfried Reich has left eFFECTOR, the biotech he co-founded to discover selective translation regulators, to take up the CSO role at Turning Point Therapeutics.
“I have followed the progress Turning Point has made, and was drawn… […]